Previous Close | 4.1600 |
Open | 4.2110 |
Bid | 3.8200 x 800 |
Ask | 0.0000 x 1800 |
Day's Range | 4.2110 - 4.4003 |
52 Week Range | 3.4900 - 11.9520 |
Volume | |
Avg. Volume | 31,069 |
Market Cap | 32.073M |
Beta (5Y Monthly) | 0.85 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Delcath Systems Inc (NASDAQ: DCTH) announced further details regarding presentations relating to its proprietary percutaneous hepatic perfusion (PHP) system. The CHOPIN trial assessed ipilimumab plus nivolumab (IPI+NIVO) combined with Delcath's proprietary liver-targeted PHP treatment in metastatic uveal melanoma patients. The poster reports a Best Overall Response of 1 complete response, five partial responses, and one stable disease accounting for an Objective Response Rate of 85.7%. Related:
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Delcath Systems Inc's (NASDAQ: DCTH) single-institution retrospective study data on CHEMOSAT Hepatic Delivery System for liver dominant metastatic uveal melanoma (mUM) were published in the journal Melanoma Research. 41 of 81 (50.6%) patients had received other treatments, either systemic or liver-directed, before percutaneous hepatic perfusion (PHP) treatment. 250 PHP procedures were performed in 81 patients. The Company's PHP system is designed to administer high-dose chemotherapy to the liver